[
    [
        {
            "time": "2019-04-17",
            "original_text": "A股头条之上市公司公告精选（4.17）",
            "features": {
                "keywords": [
                    "上市公司",
                    "公告",
                    "精选"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股头条之上市公司公告精选（4.17）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "上市公司业绩精选：恒瑞医药一季度净利11.9亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季度",
                    "净利",
                    "11.9亿"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上市公司业绩精选：恒瑞医药一季度净利11.9亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "恒瑞医药(600276.SH)一季度净利润升25.61%至11.93亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季度",
                    "净利润",
                    "增长",
                    "25.61%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)一季度净利润升25.61%至11.93亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "恒瑞医药：一季度净利11.93亿元 同比增26%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季度",
                    "净利",
                    "增长",
                    "26%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：一季度净利11.93亿元 同比增26%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "恒瑞医药一季报：一季度净利11.93亿元，同比增长25.61%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季报",
                    "净利",
                    "增长",
                    "25.61%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药一季报：一季度净利11.93亿元，同比增长25.61%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "外强中干的太极集团",
            "features": {
                "keywords": [
                    "太极集团",
                    "外强中干"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "外强中干的太极集团",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "93个重点产品中标价与医疗机构采购量曝光",
            "features": {
                "keywords": [
                    "重点产品",
                    "中标价",
                    "采购量",
                    "曝光"
                ],
                "sentiment_score": 0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "93个重点产品中标价与医疗机构采购量曝光",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "“4+7”带量采购政策下的行业发展机遇",
            "features": {
                "keywords": [
                    "4+7",
                    "带量采购",
                    "政策",
                    "机遇"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“4+7”带量采购政策下的行业发展机遇",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "2018医药生物企业成绩单出炉，整体表现良好",
            "features": {
                "keywords": [
                    "医药生物",
                    "成绩单",
                    "整体表现",
                    "良好"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2018医药生物企业成绩单出炉，整体表现良好",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "恒瑞系老板娘掌舵，高瓴博裕入场站队，年内最重磅医药IPO来了",
            "features": {
                "keywords": [
                    "恒瑞系",
                    "老板娘",
                    "高瓴博裕",
                    "IPO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞系老板娘掌舵，高瓴博裕入场站队，年内最重磅医药IPO来了",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "[天风医药] 贝达药业：埃克替尼销量高速增长，新品种步入收获期有望迎来业绩拐点",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "销量",
                    "增长",
                    "新品种",
                    "业绩拐点"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[天风医药] 贝达药业：埃克替尼销量高速增长，新品种步入收获期有望迎来业绩拐点",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "[天风医药] 片仔癀：2018年业绩实现高增长，2019年有望延续良好的发展态势",
            "features": {
                "keywords": [
                    "片仔癀",
                    "2018年",
                    "业绩",
                    "高增长",
                    "2019年",
                    "延续"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[天风医药] 片仔癀：2018年业绩实现高增长，2019年有望延续良好的发展态势",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "[天风医药] 健帆生物：一季度维持高增长，业绩实现开门红",
            "features": {
                "keywords": [
                    "健帆生物",
                    "一季度",
                    "高增长",
                    "开门红"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[天风医药] 健帆生物：一季度维持高增长，业绩实现开门红",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-16",
            "original_text": "[招商策略] 年初以来全球市场走势背后的科技趋势——观策天夏第九话（0416）",
            "features": {
                "keywords": [
                    "全球市场",
                    "走势",
                    "科技趋势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[招商策略] 年初以来全球市场走势背后的科技趋势——观策天夏第九话（0416）",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]